Below are the most recent publications written about "Benzoates" by people in Profiles.
-
Camm AJ, Piccini JP, Alings M, Dorian P, Gosselin G, Guertin MC, Ip JE, Kowey PR, Mond?sert B, Prins FJ, Roux JF, Stambler BS, van Eck J, Al Windy N, Thermil N, Shardonofsky S, Bharucha DB, Roy D. Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201). Circ Arrhythm Electrophysiol. 2023 12; 16(12):639-650.
-
Stambler BS, Camm AJ, Alings M, Dorian P, Heidbuchel H, Houtgraaf J, Kowey PR, Merino JL, Mond?sert B, Piccini JP, Pokorney SD, Sager PT, Verma A, Wharton JM, Bharucha DB, Plat F, Shardonofsky S, Chen M, Ip JE. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial. Lancet. 2023 07 08; 402(10396):118-128.
-
Wong JC, Shiuey EJ, Razeghinejad R, Shukla AG, Kolomeyer NN, Myers JS, Pro MJ, Lee D. The effectiveness and tolerability of fixed-dose combination netarsudil 0.02%/latanoprost 0.005% at a tertiary glaucoma center. Graefes Arch Clin Exp Ophthalmol. 2023 Jan; 261(1):193-200.
-
Shiuey EJ, Mehran NA, Ustaoglu M, Zhang Q, Razeghinejad R, Shukla AG, Kolomeyer NN, Myers JS, Lee D. The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes. Graefes Arch Clin Exp Ophthalmol. 2022 Mar; 260(3):967-974.
-
Syed ZA, Rapuano CJ. Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease. Curr Opin Ophthalmol. 2021 May 01; 32(3):268-274.
-
Ostler E, Rhee D, Burney E, Sozeri Y. Advances in medical therapy for glaucoma. Curr Opin Ophthalmol. 2021 Mar 01; 32(2):129-133.
-
Rapuano PB, Levin AV, Price JM, Myers JS, Lee D, Shukla AG. Early Experience with Netarsudil in Pediatric Patients: A Retrospective Case Series. Ophthalmol Glaucoma. 2021 Mar-Apr; 4(2):232-234.
-
Singh IP, Fechtner RD, Myers JS, Kim T, Usner DW, McKee H, Sheng H, Lewis RA, Heah T, Kopczynski CC. Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension. J Glaucoma. 2020 10; 29(10):878-884.
-
Nevil G, Roth M, Gill J, Zhang W, Teicher B, Erickson SW, Gatto G, Smith M, Kolb EA, Gorlick R. Initial in?vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. Pediatr Hematol Oncol. 2021 Feb; 38(1):8-13.
-
Lin MM, Moster SJ, Zheng CX, Anderson-Qui?ones CD, Katz LJ, Pro MJ, Myers JS, Moster MR, Lee D. Netarsudil's Effect in Eyes with a History of Selective Laser Trabeculoplasty. Ophthalmol Glaucoma. 2020 Jul - Aug; 3(4):306-308.